An open virtual meeting of Idaho IMPAC is scheduled June 10, 2020, 5:45 – 7:45 MT: You are encouraged to attend if you have comments to submit or want to learn more background on Medicare proposed LCDs before they go into effect.   

Note:  This meeting is an informational meeting and will not discuss claims issues or anything that might violate privacy rules. Log-in information can be found below.

https://global.gotomeeting.com/join/896540461

United States (Toll Free): 1 866 899 4679

Access Code: 896-540-461

Noridian Medicare has five Draft Local Coverage Determinations (LCDs) open for comment. The LCDs will be discussed at the open IMPAC (former CAC) meeting on June 10. If you would like to submit comments for any of the draft LCDs, please include a copy to the IMA and send to:

Noridian Medicare JF Part B
Attention: Proposed LCD Comments
PO Box 6781
Fargo, ND 58108-6781

IMA
Attention: Pam - Draft LCD Comments
PO Box 2668
Boise, ID 83701

Submit comments by email: policydraft@noridian.com and pam@idmed.org

Draft LCDs:
Implantable Continuous Glucose Monitor (I-CGM) – Comment period ends 7/4/2020
Lab: Urine Drug Testing - Comment period ends 7/12/2020
MoIDX: Breast Cancer IndexTM (BCI) Gene Expression Test - Comment period ends 7/12/2020
MoIDX: EndoPredict Breast Cancer Gene Expression Test - Comment period ends 7/12/2020
MoIDX: Liquid Biopsies for Solid Organ Transplantation - Comment period ends 7/12/2020

Noridian maintains an IMPAC for each state within Jurisdiction F with the purpose of offering:
• A formal mechanism for physicians in state to be informed of LCD development,
• A mechanism to discuss and improve administrative policies that are within carrier discretion
• A forum for information exchange between Noridian and physicians.

The focus of the IMPAC is to discuss issues presented in each state, administrative policies and to get the latest updates from CMS and our Provider Outreach teams. The Noridian IMPAC does not address issues and policies related to private insurance business, is not a forum for peer review, and is not an avenue for discussion of individual cases, claims, or providers.